SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
Biopharma Update on the Novel Coronavirus: September 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
September 17, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Exicure Announces Positive Phase Ib Trial Results for Solid Tumor Treatment Cavrotolimod
Exicure announced positive results from its Phase Ib trial evaluating cavrotolimod, its SNA-enabled TLR9 agonist, that is being developed for the treatment of solid tumors, in combination with pembrolizumab.
September 17, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Biopharma Update on the Novel Coronavirus: September 16
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
September 16, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 14
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
September 14, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: September 7-11
It was a busy week for clinical trial updates. Here’s a look.
September 11, 2020
 · 
10 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: September 11
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
September 10, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 9
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
September 8, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Use of AI in medical field.
Drug Development
AI in Medical Field for Clinical Trials Increase, Refining Endpoints, Quantifying Pain, & More
Ai in medical field is helping the researchers at clinical stage research by increasing the efficiency, refining endpoints and quantifying pain, and much more.
September 4, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
Clinical Catch-Up: August 31-September 4
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
September 4, 2020
 · 
9 min read
 · 
Mark Terry
Pictured: A person performing a COVID-19 test/iSto
Drug Development
NanoViricides Outlines Two-Pronged Approach to Developing COVID-19 Therapies
NanoViricides, based in Shelton, Connecticut, outlined its approach to developing therapies against COVID-19 at the LD 500 investor conference yesterday.
September 4, 2020
 · 
3 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Press Releases
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
July 15, 2024
 · 
5 min read
Press Releases
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
July 12, 2024
 · 
9 min read
Press Releases
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
July 12, 2024
 · 
7 min read
Press Releases
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
July 11, 2024
 · 
7 min read
Press Releases
First Patient Dosed in Phase I Clinical Trial of YOLT-201
July 11, 2024
 · 
3 min read
Press Releases
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
July 11, 2024
 · 
2 min read
Press Releases
AusperBio Receives Breakthrough Therapy Designation for AHB-137 in Chronic Hepatitis B Treatment
July 11, 2024
 · 
4 min read
Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction
July 10, 2024
 · 
5 min read
News
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
July 10, 2024
 · 
10 min read
News
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
July 10, 2024
 · 
4 min read
Drug Development
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
July 10, 2024
 · 
13 min read
News
Gain Therapeutics Announces the Completion of Dosing of the Phase 1 Study of GT-02287
July 9, 2024
 · 
6 min read
News
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101
July 9, 2024
 · 
3 min read
FDA
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
July 9, 2024
 · 
3 min read
Drug Development
Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
July 9, 2024
 · 
3 min read
Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma
July 8, 2024
 · 
4 min read
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
July 8, 2024
 · 
4 min read
Drug Development
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
July 8, 2024
 · 
7 min read
Drug Development
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
July 8, 2024
 · 
15 min read
Drug Development
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
July 8, 2024
 · 
4 min read
Load More